| Last Price$0.08 | Day Change (%)14.29% |
| Open Price$0.08 | Day Change ($)0.01 |
| Day Range0.08–0.08 | 52-Week Range0.05–0.29 |
As of Mon 04/29/2013 06:24 PM EDT | USD
Ladies and gentlemen, thank you for standing by. Welcome to the Alcon Incorporated Earnings Conference Call for the Third Quarter of 2010. During the presentation, all participants will be on a listen-only mode. Afterwards, you will be invited to participate in the question-and-answer session. (Operator Instructions).
The stocks mentioned in this article be holdings in the managed portfolios of Validea Capital Management, a separate asset management firm founded by Validea.com founder John Reese. Validea Capital Management, which an SEC registered investment advisory firm and a separate company from Validea.com, ...
Good morning and good afternoon. Welcome to the Novartis Q1 2013 Results Conference Call and Audio Webcast. Please note that during the presentation all participants will be in listen-only mode and the conference is being recorded.
Analyst Phil Gorham sizes up Nestle's next move now that has purchased Kraft's frozen pizza business, sold its stake in Alcon , and decided not to bid for Cadbury.
Good morning and good afternoon and welcome to the Novartis Q4 Full Year 2012 Results Conference Call and Live Video Webcast. Please note that during the presentation all participants will be in listen-only mode and the conference is being recorded. A recording of the conference call, including the ...
Four offerings deemed to be right for right now.
BBH Core Select manager Tim Hartch says focusing on easy-to-understand businesses, particularly in the financials and consumer defensive sectors, helps his team avoid negative surprises.
Good morning and good afternoon and welcome to the Novartis Q3 nine months 2012 Results Conference Call and Live Webcast. Please note that during the presentation, all participants will be in listen-only mode and the conference is being recorded. A recording of the conference call including the QnA ...
A large generics business and niche pipeline keep Novartis ahead of the curve.